Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
REDWOOD CITY, Calif., July 26, 2017 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report second quarter 2017 financial results on Wednesday August 2nd, 2017. OncoMed management will host a conference call and webcast to review 2017 second-quarter financial results and provide a corporate update at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-855-420-0692 (domestic) and 1-484-756-4194 (international) using the conference ID# 61373816. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com, and will be available for replay through November 30th, 2017.
An audio replay of the conference call can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliances with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. The Company is also evaluating potential partnering opportunities for vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28). For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact Peter Rahmer Trout Group [email protected] (646) 378-2973 Mike Zanoni Trout Group [email protected] (646) 378-2924
